Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies.

Kazda, Christof M et al.·Diabetes care·2016·
RPEP-029852016RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Key Numbers

How They Did This

Why This Research Matters

What This Study Doesn't Tell Us

Trust & Context

Original Title:
Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies.
Published In:
Diabetes care, 39(7), 1241-9 (2016)
Database ID:
RPEP-02985

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-02985·https://rethinkpeptides.com/research/RPEP-02985

APA

Kazda, Christof M; Ding, Ying; Kelly, Ronan P; Garhyan, Parag; Shi, Chunxue; Lim, Chay Ngee; Fu, Haoda; Watson, David E; Lewin, Andrew J; Landschulz, William H; Deeg, Mark A; Moller, David E; Hardy, Thomas A. (2016). Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies.. Diabetes care, 39(7), 1241-9. https://doi.org/10.2337/dc15-1643

MLA

Kazda, Christof M, et al. "Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies.." Diabetes care, 2016. https://doi.org/10.2337/dc15-1643

RethinkPeptides

RethinkPeptides Research Database. "Evaluation of Efficacy and Safety of the Glucagon Receptor A..." RPEP-02985. Retrieved from https://rethinkpeptides.com/research/kazda-2016-evaluation-of-efficacy-and

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.